依达拉奉右莰醇对急性脑梗死患者血清NSE及S100β的相关研究  

Correlation study of Edaravone and Dexborneol on serum NSE and S100βin patients with acute cerebral infarction

作　　者：甘本辉 陈龙雯 朱颖 聂美玲 刘丹 Gan Benhui;Chen Longwen;Zhu Ying;Nie Meiling;Liu Dan(Fengcheng People's Hospital,Yichun,Jiangxi 331100,China)

机构地区：[1]江西省丰城市人民医院,江西宜春331100

出　　处：《首都食品与医药》2025年第3期77-79,共3页Capital Food Medicine

基　　金：江西省卫生健康委科技计划项目(编号:202312250)。

摘　　要：目的探讨依达拉奉右莰醇对急性脑梗死患者血清神经元特异性烯醇化酶(NSE)及S100β蛋白的影响.方法研究对象共72例,均为2023年1月-2024年5月在丰城市人民医院神经内科治疗的急性脑梗死患者,根据随机数表法分为观察组36例和对照组36例.对照组进行常规治疗,观察组在对照组治疗基础上进行依达拉奉右莰醇治疗.两组均连续治疗14天.对比两组临床疗效,治疗前、治疗14天后血清NSE、S100β蛋白变化、神经功能缺损情况及治疗期间不良反应发生率.结果观察组治疗总有效率(88.89%)高于对照组(66.67%);治疗14天后,观察组血清NSE水平、S100β蛋白水平、NIHSS量表评分低于对照组(P<0.05);两组不良反应发生率对比,无明显差异(P>0.05).结论依达拉奉右莰醇在急性脑梗死患者的治疗中,能够有效降低血清NSE及S100β的水平,进而改善神经功能状态,显著提升临床治疗效果.Objective To investigate the effects of Edaravone and Dexborneol on serum neuron-specific enolase(NSE)and S100βprotein in patients with acute cerebral infarction.Methods A total of 72 patients with acute cerebral infarction were treated in the neurology department of Fengcheng People's Hospital from January 2023 to May 2024.They were randomly divided into an observation group of 36 cases and a control group of 36 cases using a random number table method.The control group received routine treatment,while the observation group received Edaravone and Dexborneol treatment on the basis of the control group's treatment.Both groups were treated continuously for 14 days.Compare the clinical efficacy of two groups,including changes in serum NSE and S100βprotein levels before and after 14 days of treatment,neurological deficits,and incidence of adverse reactions during treatment.Results The total effective rate of the observation group(88.89%)was higher than that of the control group(66.67%);after 14 days of treatment,the serum NSE level,S100βprotein level,and NIHSS score in the observation group were lower than those in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Edaravone and Dexborneol can effectively reduce the levels of serum NSE and S100βin patients with acute cerebral infarction,thereby improving neurological function and significantly enhancing clinical treatment efficacy.

关 键 词：急性脑梗死 依达拉奉右莰醇 神经元特异性烯醇化酶 S100Β蛋白 

分 类 号：R743.33[医药卫生—神经病学与精神病学]